Cost effectiveness of HMG-CoA reductase inhibition in Canada.

OBJECTIVE To assess the cost effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor therapy, particularly atorvastatin, in primary and secondary prevention of coronary artery disease (CAD) in Canada. METHODS A Markov model was developed in which costs and effectiveness of atorvastatin were compared with those of other statins… CONTINUE READING